BioToxTech Highlights 'Ten-Bagger' Performance with Approximately 13 Billion Won Profit from G2GBIO Investment

BioToxTech, the top toxicology testing institution in Korea, has reported strong investment returns by generating approximately 13 billion won in profit from its investment in G2GBIO.

According to BioToxTech, the company invested a total of 1 billion won in G2GBIO at 7,000 won per share, acquiring 150,000 shares. Based on G2GBIO’s closing price on March 17, the investment is now valued at about 13 billion won, resulting in a return of approximately 13 times the initial investment. This performance surpasses the so-called “ten-bagger” benchmark, with the realized profit representing about 25% of BioToxTech’s market capitalization of roughly 52 billion won.

Last year, BioToxTech signed an agreement to provide exclusive preclinical research services related to the development of treatments for obesity, diabetes, dementia, prostate cancer, and hair loss.

Kang Jonggu, Chairman of BioToxTech, stated, “We achieved higher-than-expected returns while collaborating with G2GBIO on joint development projects in response to the evolving bio market environment for obesity, diabetes, and hair loss treatments. We plan to continue contributing to the global licensing out and commercialization efforts of domestic bio companies, including supporting their FDA qualification and certification processes.”

G2GBIO has been advancing the development of obesity treatments in partnership with Samsung Bio and has signed contracts for two types of semaglutide. The company also secured an investment of 20 billion won from EPIS Holdings and is currently conducting joint platform research with EPIS NexLab. Major investors such as Daily Partners and Atinum Investment, which previously invested around 150 billion won in G2GBIO, are reported to have already achieved returns exceeding the ten-bagger threshold and are now making additional investments.

Industry insiders believe that the combination of policy support for domestic bio companies and the global wave of patent expirations is driving significant growth potential for the entire sector. One industry official commented, “As toxicology research institutions play an essential foundational role in the growth of the bio industry, the concurrent growth of related companies is expected to accelerate in earnest.”

This content was produced with the assistance of AI translation services.